- Home
- CNTB vs CRBP Comparison
CNTB vs CRBP Comparison
Compare CNTB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- CRBP
- Stock Information
- Founded
- CNTB 2012
- CRBP 2009
- Country
- CNTB United States
- CRBP United States
- Employees
- CNTB N/A
- CRBP N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- CRBP Health Care
- Exchange
- CNTB Nasdaq
- CRBP Nasdaq
- Market Cap
- CNTB 114.8M
- CRBP 114.8M
- IPO Year
- CNTB 2021
- CRBP N/A
- Fundamental
- Price
- CNTB $1.57
- CRBP $9.50
- Analyst Decision
- CNTB Strong Buy
- CRBP Strong Buy
- Analyst Count
- CNTB 2
- CRBP 10
- Target Price
- CNTB $7.50
- CRBP $53.22
- AVG Volume (30 Days)
- CNTB 184.6K
- CRBP 91.8K
- Earning Date
- CNTB 09-05-2025
- CRBP 11-06-2025
- Dividend Yield
- CNTB N/A
- CRBP N/A
- EPS Growth
- CNTB N/A
- CRBP N/A
- EPS
- CNTB N/A
- CRBP N/A
- Revenue
- CNTB $1,965,000.00
- CRBP N/A
- Revenue This Year
- CNTB N/A
- CRBP N/A
- Revenue Next Year
- CNTB N/A
- CRBP $220.04
- P/E Ratio
- CNTB N/A
- CRBP N/A
- Revenue Growth
- CNTB N/A
- CRBP N/A
- 52 Week Low
- CNTB $1.56
- CRBP $4.64
- 52 Week High
- CNTB $2.20
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- CNTB 39.75
- CRBP 49.85
- Support Level
- CNTB $1.63
- CRBP $9.42
- Resistance Level
- CNTB $1.79
- CRBP $9.73
- Average True Range (ATR)
- CNTB 0.18
- CRBP 0.51
- MACD
- CNTB -0.04
- CRBP -0.08
- Stochastic Oscillator
- CNTB 0.39
- CRBP 15.33
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.